CEL-SCI CORPORATION (CVM) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2023-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2023-06-30..
Cash and securities
Overview →Financial period ending 2023-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2023-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2023-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 5.14M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2023-06-30 | (m) | (m) | $5.14M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $10.05M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $18.02M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $22.67M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $28.07M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $34.28M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $37.11M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $36.06M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $35.96M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $6.43M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $21.86M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $15.51M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $20.14M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $14.33M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $9.38M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $8.44M | (m) | (m) |
| 2019-06-30 | (m) | (m) | $9.49M | (m) | (m) |
| 2019-03-31 | (m) | (m) | $5.51M | (m) | (m) |
| 2018-12-31 | (m) | (m) | $6.68M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $10.31M | (m) | (m) |
| 2018-06-30 | (m) | (m) | $2.35M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $3.06M | (m) | (m) |
| 2017-12-31 | (m) | (m) | $2.14M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $2.37M | (m) | (m) |
| 2017-06-30 | (m) | (m) | $1.23M | (m) | (m) |
| 2017-03-31 | (m) | (m) | $1.53M | (m) | (m) |
| 2016-12-31 | (m) | (m) | $2.39M | (m) | (m) |
| 2016-09-30 | (m) | (m) | $2.92M | (m) | (m) |
| 2016-06-30 | (m) | (m) | $5.22M | (m) | (m) |
| 2016-03-31 | (m) | (m) | $6.05M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $10.42M | (m) | (m) |
| 2015-09-30 | (m) | (m) | $5.73M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $11.23M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $2.61M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $9.46M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $8.51M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $14.29M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $10.61M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $13.49M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $41.61K | (m) | (m) |
| 2013-06-30 | (m) | (m) | $3.48M | (m) | (m) |
| 2013-03-31 | (m) | (m) | $6.99M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $10.74M | (m) | (m) |
| 2012-09-30 | (m) | (m) | $3.94M | (m) | (m) |
| 2012-06-30 | (m) | (m) | $7.22M | (m) | (m) |
| 2012-03-31 | (m) | (m) | $5.27M | (m) | (m) |
| 2011-12-31 | (m) | (m) | $3.46M | (m) | (m) |
| 2011-09-30 | (m) | (m) | $4.26M | (m) | (m) |
| 2011-06-30 | (m) | (m) | $10.58M | (m) | (m) |
| 2011-03-31 | (m) | (m) | $17.74M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $20.85M | (m) | (m) |
| 2010-09-30 | (m) | (m) | $26.57M | (m) | (m) |
| 2010-06-30 | (m) | (m) | $30.48M | (m) | (m) |
| 2009-09-30 | (m) | (m) | $33.57M | (m) | (m) |
| 2008-09-30 | (m) | (m) | $711.26K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |